2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 8, 2015

9:00AM-11:00AM: Abstract Number: 327

The Relation of Plasma Vitamin K Status to Meniscal Pathology in Knee Osteoarthritis: The Multicenter Osteoarthritis Study

Osteoarthritis - Clinical Aspects Poster I: Treatments and Metabolic Risk Factors

9:00AM-11:00AM: Abstract Number: 552

The Relationship Between Efficacy and Toxicity in Patients with Rheumatoid Arthritis Receiving Methotrexate in Combination with Adalimumab

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster I

9:00AM-11:00AM: Abstract Number: 376

The Relationships Between Bone Mineral Density and Radiographic Features of Hand or Knee Osteoarthritis in Older Adults: Data from the Dong-Gu Study

Osteoporosis and Metabolic Bone Disease - Clinical Aspects and Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 426

The Risk of Hospitalized Infection Following Initiation of Biologic Agents Versus Methotrexate in the Treatment of Juvenile Idiopathic Arthritis

Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster I: Lupus, Scleroderma, JDMS

9:00AM-11:00AM: Abstract Number: 239

The Role of Dual Energy Computed Tomography in Diagnosing Acute Gouty Arthritis: Comparison with Ultrasound and Aspiration

Metabolic and Crystal Arthropathies Poster I

9:00AM-11:00AM: Abstract Number: 874

The Short Term Damage Burden in Vasculitis and Vasculitis Mimics As Measured By the Vasculitis Damage Index

Vasculitis Poster I

9:00AM-11:00AM: Abstract Number: 14

The SLE Susceptibility Gene Macrophage Migration Inhibitory Factor Serves As an Upstream Regulator of NLRP3 (NOD-like receptor family pyrin domain containing 3) Expression and Subsequent IL-1beta Production in Human Monocytes in Response to Lupus U1-snRNP Immune Complex

Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis Poster I

9:00AM-11:00AM: Abstract Number: 68

The Stroop Word-Naming Test in Fibromyalgia Patients

Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes Poster I

9:00AM-11:00AM: Abstract Number: 832

The Validity and Reliability of Online Obituaries As a Source of Mortality Data

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster I

9:00AM-11:00AM: Abstract Number: 81

The Value of Routine Use of Creatine Kinase and Thyroid Stimulating Hormone Tests in Patients with Suspected Fibromyalgia: Results of a Cross-Sectional Study

Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes Poster I

9:00AM-11:00AM: Abstract Number: 612

Thromboembolic Events Are Not Associated with Anti-Adalimumab Antibodies

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster I

9:00AM-11:00AM: Abstract Number: 481

Time to Disease-Modifying Anti-Rheumatic Drug Treatment for New Patients with Rheumatoid Arthritis – Single Center Experience

Rheumatoid Arthritis - Clinical Aspects Poster I

9:00AM-11:00AM: Abstract Number: 614

Time to First Signs of Loss of Response in Rheumatoid Arthritis Patients Treated with Anti TNF Agents: Correlations with Serum Drug Level, Immunogenicity and Csdmard Association

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster I

9:00AM-11:00AM: Abstract Number: 586

Titer of Anti-Citrullinated Peptide Antibody Affects the Efficacy of First Biological Treatment in Rheumatoid Arthritis

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster I

9:00AM-11:00AM: Abstract Number: 268

TLR4 Endogenous Ligand S100A8/A9 Levels in Adult-Onset Still’s Disease and Their Association with Disease Activity and Clinical Manifestations

Miscellaneous Rheumatic and Inflammatory Diseases Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].